793 results on '"Pincus, T."'
Search Results
2. Response to Dr. Wolfe
3. The feasibility and acceptability of a physical activity intervention for older people with chronic musculoskeletal pain: The iPOPP pilot trial protocol*
4. Osteoarthritis Patients With Pain Scores More Than 8/10 Should Be Analyzed Separately Or Excluded From Clinical Trial Protocols, As 72% Screen Positive For Fibromyalgia And/Or Depression On A Multidimensional Health Assessment Questionnaire
5. Low back pain patients’ responses to videos of avoided movements
6. Will shared decision making between patients with chronic musculoskeletal pain and physiotherapists, osteopaths and chiropractors improve patient care?
7. HOW MUSCULOSKELETAL PRACTITIONERS IN THE PRIVATE SECTOR PERCEIVE THEIR ROLE IN MAINTAINING PEOPLE WITH BACK PAIN AT WORK
8. Patients' satisfaction with osteopathic and GP management of low back pain in the same surgery
9. BRAIN SCANNING BACK PAIN PATIENTS PRESENTED WITH MOVEMENTS THEY ‘FEAR’
10. Limitations of randomized controlled clinical trials to depict accurately long-term outcomes in rheumatoid arthritis
11. Efficacy of prednisone 1–4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial
12. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST–RA database
13. COGNITIVE BIAS IN CHRONIC PAIN: 46
14. Topical Seminar Summary: PAIN-RELATED FEAR IN CHRONIC PAIN: 39
15. Test–retest reliability of disease activity core set measures and indices in rheumatoid arthritis
16. THE INFLUENCE OF HEALTH OUTCOME ON THE CONSULTING BEHAVIOUR OF PATIENTS WITH CHRONIC MUSCULOSKELETAL PAIN
17. INFLUENCES ON PATIENTSʼ AND PRACTITIONERSʼ DECISION MAKING REGARDING THE PROCESS OF PRIMARY CARE FOR CHRONIC MUSCULOSKELETAL PAIN
18. Reporting Disease Activity in Clinical Trials of Patients With Rheumatoid Arthritis: EULAR/ACR Collaborative Recommendations
19. Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States
20. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
21. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures
22. A PROPOSAL FOR A MINIMAL COMPREHENSIVE LIST OF FACTORS FOR PROSPECTIVE COHORTS IN BACK PAIN; THE MULTINATIONAL MUSCULOSKELETAL INCEPTION COHORT STUDY STATEMENT
23. Prevalence and comparative troublesomeness by age of musculoskeletal pain in different body locations
24. Chronic musculoskeletal pain rarely presents in a single body site: results from a UK population study
25. Most people over age 50 in the general population do not meet ACR remission criteria or OMERACT minimal disease activity criteria for rheumatoid arthritis
26. Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US
27. Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities
28. Declines in number of tender and swollen joints in patients with rheumatoid arthritis seen in standard care in 1985 versus 2001: possible considerations for revision of inclusion criteria for clinical trials
29. Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count
30. Should aggressive therapy for rheumatoid arthritis require early use of weekly low-dose methotrexate, as the first disease-modifying anti-rheumatic drug in most patients?
31. Disparities in health according to socioeconomic status
32. Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities
33. How aggressive should initial therapy for rheumatoid arthritis be?
34. Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa?
35. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis
36. Do rheumatology cost-effectiveness analyses make sense?
37. Understanding the process of care for musculoskeletal conditions—why a biomedical approach is inadequate
38. An Index of the Three Core Data Set Patient Questionnaire Measures Distinguishes Efficacy of Active Treatment From That of Placebo as Effectively as the American College of Rheumatology 20% Response Criteria (ACR20) or the Disease Activity Score (DAS) in a Rheumatoid Arthritis Clinical Trial
39. Third International Symposium for health professionals in rheumatology: Enschede 6–9 June 1990
40. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review
41. RECALL BIAS, PAIN, DEPRESSION AND COST IN BACK PAIN PATIENTS
42. A SYSTEMATIC REVIEW OF PSYCHOLOGICAL FACTORS AS PREDICTORS OF CHRONICITY/DISABILITY IN PROSPECTIVE COHORTS OF LOW BACK PAIN
43. Usefulness of the HAQ in the clinic
44. A Randomized, Double-Blind, Crossover Clinical Trial of Diclofenac Plus Misoprostol Versus Acetaminophen in Patients With Osteoarthritis of the Hip or Knee
45. Combination therapy for rheumatoid arthritis with methotrexate and cyclosporine
46. PATIENTS WITH RHEUMATOID ARTHRITIS CLASSIFIED AS "HIGH ACTIVITY" ACCORDING TO DAS28 OR CDAI INCLUDE 55% AND 70% WHO SCREEN POSITIVE FOR DEPRESSION AND 67% AND 80% WHO SCREEN POSITIVE FOR FIBROMYALGIA, RESPECTIVELY.
47. RHEUMETRIC QUANTITATIVE 0-10 PHYSICIAN ESTIMATES OF INFLAMMATION, DAMAGE, AND DISTRESS IN RHEUMATOID ARTHRITIS: VALIDATION AGAINST REFERENCE MEASURES.
48. INFLAMMATION IS MORE PROMINENT THAN JOINT DAMAGE AT INITIAL VISITS OF PATIENTS WITH INFLAMMATORY ARTHRITIDES, BUT ORGAN DAMAGE AND PATIENT DISTRESS ARE AS PROMINENT IN OVERALL RHEUMATOLOGY CARE: DATA FROM A FEASIBLE PHYSICIAN RHEUMATIC CHECKLIST.
49. Patients with osteoarthritis or rheumatoid arthritis have similar severity of pain and functional disability when compared according to the same patient questionnaire measure: data from 1979-2019
50. Disease burden in osteoarthritis (OA) is similar to rheumatoid arthritis (RA) from the patient’s perspective, slightly higher in ra at presentation, similar one year later, and slightly higher in oa two years later
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.